Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Mesotherapy

Also known as: injectable mesotherapy, meso injections

Mesotherapy delivers substances through multiple small injections into the skin. In aesthetic practice, different preparations are used for goals such as improving skin appearance. The product, purpose and clinical assessment determine what treatment is being offered.

In plain English — Mesotherapy places a preparation into the skin through small injections. Some tested preparations have improved skin appearance in clinical trials. The exact product and a medical assessment matter because both the expected benefit and the risks depend on what is being injected.

Evidence status

Emerging

Product-specific human evidence; variable certainty. Controlled trials report appearance benefits for particular hyaluronic-acid preparations, while a small study of another formulation found no significant clinical or histological benefit. Formulations, comparators and outcomes differ, so the technique name alone does not establish an effect. Injection assessment and product-specific safety remain central.

What mesotherapy is and the preparations encountered#

Mesotherapy is a delivery approach. In aesthetic use, injections may contain hyaluronic acid (HA), amino acids or other substances in different combinations. A useful description therefore names both the technique and the preparation. Clinical trials have evaluated specific HA-based products for facial skin appearance rather than one standard substance called mesotherapy.[1, 2, 3]

Some of these treatments overlap with the category described in skin boosters. That entry reviews the broader injectable skin-quality category; this one concentrates on mesotherapy terminology, formulation-specific evidence and injection assessment. Products promoted for fat dissolution have a different purpose and risk profile. Their evidence should be evaluated separately.[1, 2, 16]i

“No-needle mesotherapy” is also used commercially for delivery approaches without injection. Establish what actually happens to the skin before deciding which evidence and practice requirements apply.[1, 2, 16]i

Use of mesotherapy in aesthetic practice#

The consultation begins with the intended change: for example, facial appearance or a particular skin-quality concern. Record the proposed product, supporting evidence and relevant medical history, then consider whether an injection is appropriate for that person. Training in a technique, product conformity and professional authority are separate requirements.[2, 3, 17]i[14]i

England

DHSC’s 2023 consultation and 2025 response describe proposed licensing and restrictions. The earlier proposed list placed mesotherapy separately from certain HA and vitamin/mineral injections, illustrating why contents and purpose matter alongside a treatment name. These documents do not themselves create a completed operator scheme. The parliamentary committee’s September 2026 account reported delays to further consultation. Check operative requirements when arranging a service.[1, 5, 6]

The 2021 children legislation already addresses cosmetic filler injections in under-18s, with defined purposes and statutory defences. Whether a particular mesotherapy use meets its filler definition needs assessment; the word “mesotherapy” is not a legal exemption.[7]i

Scotland

The 2026 Act expressly includes specified cosmetic injections into or under skin. Its first commencement instrument brought several provisions into force in July 2026, but not the under-18 offence in section 2(1) or premises offence in section 3. Section 3 cannot commence before 6 September 2027; that limit does not itself appoint its start date. Service planning requires the relevant provisions and subsequent commencement measures to be checked together.[8, 9]

Wales

The special-procedures scheme covers acupuncture, body piercing, electrolysis and tattooing. It is not a general mesotherapy operator licence. The actual service must also be assessed against any other applicable healthcare, product, premises and professional requirements; a procedure’s absence from that four-item list does not settle those questions.[10, 11]i

Northern Ireland

An April 2026 ministerial answer stated that no broad non-surgical cosmetic licensing scheme was planned within the remaining mandate. RQIA nevertheless already registers defined independent healthcare services. Establish the status of the actual service rather than importing England’s proposals or assuming that no oversight applies.[12, 13]

For products regulated as devices, GB and Northern Ireland have different market frameworks. Verify the exact product’s conformity, supply and registration requirements under the applicable framework. MHRA’s device-market guidance does not authorise an individual to inject.[14]i

Contraindications and cautions#

An injectable preparation needs its own assessment. For relevant HA/filler products, ingredient hypersensitivity and active infection are important exclusions. Record previous injections, current medicines, allergy history and relevant medical conditions; investigate an unexplained lesion or active inflammatory problem before elective injection into that area.[17]i

Pregnancy, breastfeeding and other circumstances outside a product’s established evidence require advice from the responsible clinician and the current product information. A generic mesotherapy checklist cannot establish suitability for every medicine, device or mixture. A preparation intended for another route must not be presumed suitable for injection merely because its ingredients also appear in skincare.[17]i[14]i

Clinical uses and the evidence behind them#

A tested HA/mannitol preparation

Baspeyras and colleagues compared Glytone professional 1, a non-cross-linked HA/mannitol product, with saline on opposite cheeks. The full analysis comprised 55 women aged 34–65, with phototypes I–III, receiving three monthly sessions and follow-up to three months after the last. Radiance favoured the product at that final visit (between-side P=.012). The reported stiffness improvement was significant relative to the treated side’s baseline, but the between-side comparison was not significant (P=.063). The authors concluded positively about skin compliance and radiance. Pierre Fabre funded and conducted the study, employed nine authors and paid the investigator and assessment panel. These are results for that formulation and study setting.[2]

An HA/amino-acid formulation

A 2026 evaluator-blinded trial at six Chinese centres analysed 439 participants, predominantly women with a mean age around 35. It compared a sodium hyaluronate preparation containing four amino acids with no treatment, not sham injection. One month after the last of three monthly sessions, any improvement on the Global Aesthetic Improvement Scale occurred in 280/287 treated participants and 6/152 controls: a difference of 93.61 percentage points, 95% CI 90.04–97.19. The result supports an appearance benefit in this setting, without isolating the contribution of the amino acids. Bloomage funded the trial and employed two authors; the authors stated that the sponsor did not influence design, analysis or publication.[3]

Another formulation studied with biopsies

El-Domyati and colleagues studied six Egyptian women aged 37–49, phototypes III–IV, using a multivitamin/non-cross-linked HA preparation around the eyes. After three months of treatment and three further months of follow-up, they found no significant clinical improvement or measured collagen/elastin improvement. This small uncontrolled human study concerns that preparation and site. Egyptian educational and US NIH grants supported the work; the authors declared no conflicts.[4]

Selecting a preparation and treatment approach#

A meaningful comparison identifies the finished preparation, treatment site, desired outcome, comparator and follow-up. An appearance rating, hydration measurement and histological finding answer different questions. The person’s priorities should determine which outcome is relevant, alongside the likely recovery burden and alternatives to injection.[2, 3, 17]i

Check the supplied product information, authorised route and intended use, traceable supply and the practitioner’s ability to assess and manage complications. Mixed formulations need the same scrutiny as single-ingredient products. The responsible clinician should explain the expected benefit and uncertainty for the proposed product rather than rely on a general description of mesotherapy.[14]i[2, 3, 17]i

Adverse effects and their management#

Pain, redness, swelling and bruising can accompany injections. In the separate 57-person safety population of the HA/mannitol trial, 50 experienced post-injection events on one or both sides; most were mild or moderate, while four severe haematomas occurred on the HA side. This is the experience of that trial, not a risk percentage for every mesotherapy service.[2]

Persistent nodules, drainage or a worsening inflammatory reaction need clinical investigation. A CDC outbreak report described prolonged reactions in 14 women aged 18–63 among 20 selected recipients interviewed after mainly torso/leg treatment by one provider. One of seven aspirates grew Mycobacterium chelonae; the overall cause remained uncertain, with infectious and chemical/allergic explanations considered. The investigation demonstrates a possible complication pattern, not the incidence of contemporary facial treatment.[15]

Provide a clear route back to the treating clinician and record the product and timing when a reaction occurs. Emergency symptoms require the escalation described below, not another cosmetic treatment.[17, 18]

Referral and scope boundaries#

After relevant HA/filler injections, unusual pain, pale or grey-blue skin, visual change or stroke symptoms require immediate medical help because vascular injury can be serious. Breathing difficulty, tongue or throat swelling, or collapse requires 999 for possible anaphylaxis. The filler warning applies to that injection context; it is not a measured risk rate for all preparations called mesotherapy.[17, 18]

Persistent painful lumps, discharge or an unexplained delayed reaction need medical review. Uncertain suitability, an undiagnosed skin concern or a request outside the practitioner’s competence should be referred before treatment. The national frameworks above concern legal scope; a clinical evidence paper does not expand it.[15][17]i

Mechanism of action#

Injection places the preparation locally within the skin. For HA-containing preparations, water binding and the material’s physical behaviour provide part of the rationale for studying hydration and skin mechanics. Formulation, tissue distribution and the chosen outcome all influence how a proposed mechanism should be assessed.[2, 3]i

Added amino acids or vitamins may be proposed to influence cellular processes. Human benefit still needs to be demonstrated for the finished preparation; a plausible biochemical role is not a measured clinical response. See hyaluronic acid for the ingredient’s wider properties and photoageing for the condition being addressed in many studies.[2, 3]i

Commonly misstated claims#

Measurements of skin quality and collagen

Claim heard:“Improved elasticity or thickness proves that the injections created new collagen.”

Literature finding: The controlled trials assessed outcomes including appearance, skin mechanics and ultrasound measurements. Those endpoints do not directly quantify newly synthesised collagen.[2, 3]i

Supported statement: Report the outcome actually measured; skin-quality changes and collagen production are different claims.

The number of ingredients

Claim heard:“A cocktail works better because it contains more ingredients.”

Literature finding: No clinical rule linking a larger ingredient count to better outcomes was verified in the evidence reviewed here.[no source found]

Supported statement: Choose on evidence for the finished preparation and purpose, not ingredient count.

Product-related reactions and all injection effects

Claim heard:“The 2026 trial found that only 1.67% had any side effect.”

Literature finding: That figure was five product-related reactions among 300 safety participants: four pigment changes and one allergy. Ordinary needle-site reactions were described separately; the efficacy group had a different denominator.[3]

Supported statement: Identify the adverse-event category and safety population before quoting a percentage.

Areas of remaining uncertainty#

  • Duration: the controlled comparisons described here concentrate on short follow-up. Discuss future care without promising that a measured early benefit will persist indefinitely.[2][3]
  • Comparative choice: product-versus-saline and product-versus-no-treatment trials do not rank every available injectable. Match the comparison to the decision being made.[2][3]
  • Applicability:populations and sites differ, with limited representation of many patient groups. Use the individual’s clinical circumstances alongside the closest relevant evidence.[4]

Frequently asked questions#

Is mesotherapy the same thing as a skin booster?

The terms can overlap. Mesotherapy describes delivery, while skin booster is commonly used for a skin-quality treatment category. The actual preparation and intended effect should be named.[1, 2, 3]

What should a consultation explain?

The product, intended outcome, relevant evidence, individual suitability, expected recovery and access to help if a problem occurs. A general technique name does not supply those details.[2, 3, 17]i

Are no-needle treatments covered by the injection evidence?

No. Establish the actual delivery method and look for evidence and safety information for that method and formulation.[1, 2, 16]i

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. DHSC. The licensing of non-surgical cosmetic procedures in England. Consultation, 2023. Accessed 16 September 2026.Tier 1Supports: Mesotherapy terminology and proposed procedure categories, not an enacted licence or efficacy assessment.Funding / interest: UK government consultation; public policy source, not manufacturer evidence.
  2. Baspeyras M, Rouvrais C, Liégard L, et al. Clinical and biometrological efficacy of a hyaluronic acid-based mesotherapy product: a randomised controlled study. Arch Dermatol Res. 2013;305(8):673–682. doi:10.1007/s00403-013-1360-7.Tier 2Supports: Full primary article: French split-face cheek trial, 55 women in full analysis, ages 34–65, phototypes I–III; non-cross-linked HA/mannitol versus saline, three monthly sessions and three-month follow-up after last treatment. Endpoint-specific results and separate 57-person safety population.Funding / interest: Funded and conducted by Pierre Fabre Dermocosmetique; nine authors were employees, the clinical investigator contracted, panel paid and company-backed medical writing acknowledged.
  3. Yang R, Zhang Y, Zhao H, et al. Efficacy and Safety of a Novel Sodium Hyaluronate Composite Solution via Mesotherapy for Facial Rejuvenation: A Multicenter Randomized Controlled Study. Plast Reconstr Surg Glob Open. 2026;14(6):e7853. doi:10.1097/GOX.0000000000007853. PMID:42367716.Tier 2Supports: Full primary article: six Chinese centres, 456 enrolled and 439 analysed, predominantly women, mean age about 35; HA/amino-acid solution versus no treatment, evaluator-blinded. GAIS primary endpoint, confidence interval and distinct safety denominator.Funding / interest: Bloomage-funded; two authors affiliated with Bloomage. Authors state sponsor did not influence design, analysis or publication, and also acknowledge financial/technical support and contributions to development. Not an independently funded trial.
  4. El-Domyati M, El-Ammawi TS, Moawad O, et al. Efficacy of mesotherapy in facial rejuvenation: a histological and immunohistochemical evaluation. Int J Dermatol. 2012;51(8):913–919. doi:10.1111/j.1365-4632.2011.05184.x. PMID:22788806.Tier 3Supports: Full original uncontrolled study of six Egyptian women aged 37–49, phototypes III–IV, periorbital skin; multivitamin/HA preparation over three months with three further months' follow-up, clinical and human-biopsy endpoints.Funding / interest: Cultural and Educational Bureau of Egypt grant to Medhat and NIH R01AR28450 support to Uitto; authors declared no conflicts.
  5. DHSC. The licensing of non-surgical cosmetic procedures in England: consultation response. 7 August 2025.Tier 1Supports: England policy intentions, further consultation and implementation steps; not a completed UK-wide operator licensing scheme.Funding / interest: UK government policy document.
  6. UK Parliament, Women and Equalities Committee. Formal meeting: oral evidence session on non-surgical cosmetic procedures. 9 September 2026.Tier 1Supports: Dated committee account of delays to further consultation; policy status context, not legislation.Funding / interest: UK Parliament public record.
  7. Botulinum Toxin and Cosmetic Fillers (Children) Act 2021, section 1.Tier 1Supports: England under-18 cosmetic filler offence, defined filling purpose and statutory defences; not automatic classification of every mesotherapy mixture as a filler. Official enacted XML read.Funding / interest: UK primary legislation; no commercial sponsor.
  8. Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Act 2026, sections 1–5 and 24, schedule 1.Tier 1Supports: Covered cosmetic injection procedures and legislative framework; section 3 cannot commence before 6 September 2027. Read with source 9, not assumed fully operative at Royal Assent.Funding / interest: Scottish primary legislation; no commercial sponsor.
  9. Non-surgical Procedures and Functions of Medical Reviewers (Scotland) Act 2026 (Commencement No. 1 and Saving Provision) Regulations 2026, S.S.I. 2026/206.Tier 1Supports: Provisions commenced 22 July 2026; this instrument does not commence the section 2(1) under-18 offence or section 3 premises offence. Official XML read.Funding / interest: Scottish statutory instrument; no commercial sponsor.
  10. Public Health (Wales) Act 2017, section 57.Tier 1Supports: Four designated special procedures: acupuncture, body piercing, electrolysis and tattooing.Funding / interest: Welsh primary legislation; no commercial sponsor.
  11. Welsh Government. Licensing scheme for special procedures. Updated 30 July 2026.Tier 1Supports: Current individual licensing and premises requirements for the four designated procedures, not a general licence for all injectable aesthetics.Funding / interest: Welsh Government public guidance.
  12. Northern Ireland Assembly. AQW 41857/22-27, Minister of Health answer, 1 April 2026.Tier 1Supports: Dated statement of no plans for broad non-surgical cosmetic licensing in the remaining mandate; not exemption from other rules.Funding / interest: Northern Ireland Assembly public record.
  13. RQIA. Registration guidance. Accessed 16 September 2026.Tier 1Supports: Existing Northern Ireland registration arrangements for independent healthcare services; applicability requires assessment of the actual service.Funding / interest: Northern Ireland healthcare regulator.
  14. MHRA. Regulating medical devices in the UK. Updated 20 February 2026.Tier 1Supports: Device-market registration/conformity, distinct GB and NI arrangements; not operator entitlement or evidence for a clinical claim.Funding / interest: UK medicines and devices regulator.
  15. CDC. Outbreak of mesotherapy-associated skin reactions—District of Columbia area, January–February 2005. MMWR Morb Mortal Wkly Rep. 2005;54:1127–1130.Tier 3Supports: Primary outbreak investigation: 14 affected women among 20 selected interviewed recipients, torso/leg treatments by one provider, persistent reactions and one positive M. chelonae culture among seven aspirates. Not general incidence.Funding / interest: Public-health investigation; no commercial sponsor stated.
  16. FDA. Using Fat-Dissolving Injections That Are Not FDA Approved Can Be Harmful. Accessed 16 September 2026.Tier 1Supports: Fat-dissolving injection purpose, ingredient and harm distinction; US regulatory context, not UK product classification or authority. Older only-approved-brand wording is not used.Funding / interest: US FDA public safety communication.
  17. FDA. Dermal Fillers (Soft Tissue Fillers). Accessed 16 September 2026.Tier 1Supports: Filler-specific assessment, allergy/infection cautions and urgent symptoms of possible vascular complications; not a risk estimate for all mesotherapy.Funding / interest: US FDA public information.
  18. NHS. Anaphylaxis. Accessed 16 September 2026.Tier 4Supports: Severe allergic-reaction recognition and emergency help; patient information, not a formal evidence-graded guideline.Funding / interest: NHS public information; no product sponsorship.